The function and effectiveness of MSCs in preclinical models of diseases DOI
Z. Xie, Hu Zhou,

Tingting Ou

et al.

IntechOpen eBooks, Journal Year: 2024, Volume and Issue: unknown

Published: July 4, 2024

Mesenchymal stem cells (MSCs) have shown immense promise across diverse fields, particularly in treating various diseases. A multitude of preclinical investigations, encompassing both laboratory cellular-level studies and animal trials, demonstrated the significant effectiveness MSCs addressing a broad spectrum These collectively highlight enormous potential therapies utilizing range medical scenarios. From neurological cardiovascular disorders to autoimmune musculoskeletal disorders, including recent challenges like COVID-19, present therapeutic possibilities due their versatile capabilities. discoveries lay robust foundation for further clinical research eventual translation MSC-based treatments into mainstream practice, offering renewed optimism patients contending with complex conditions.

Language: Английский

Drug repositioning for Parkinson’s disease: an emphasis on artificial intelligence approaches DOI
Iman Karimi-Sani, Mehrdad Sharifi, Nahid Abolpour

et al.

Ageing Research Reviews, Journal Year: 2025, Volume and Issue: 104, P. 102651 - 102651

Published: Jan. 5, 2025

Language: Английский

Citations

1
An update on drug repurposing in Parkinson’s disease: Preclinical and clinical considerations DOI Open Access
Michela Salvadè, Mónica Di Luca, Fabrizio Gardoni

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2025, Volume and Issue: 183, P. 117862 - 117862

Published: Jan. 22, 2025

Language: Английский

Citations

0
From past to future: Digital approaches to success of clinical drug trials for Parkinson's disease DOI Creative Commons
Cen Cong, Madison Milne‐Ives, Ananya Ananthakrishnan

et al.

Journal of Parkinson s Disease, Journal Year: 2025, Volume and Issue: unknown

Published: April 27, 2025

Recent years have seen successes in symptomatic drugs for Parkinson's disease, but the development of treatments stopping disease progression continues to fail clinical drug trials, largely due lack efficacy drugs. This may be related limited understanding mechanisms, data heterogeneity, poor target screening and candidate selection, challenges determining optimal dosage levels, reliance on animal models, insufficient patient participation, adherence trials. Most recent applications digital health technologies artificial intelligence (AI)-based tools focused mainly stages before used AI-based algorithms or models discover novel targets, inhibitors indications, recommend candidates dosage, promote remote collection. paper reviews state literature highlights strengths limitations approaches discovery from 2021 2024, offers recommendations future research practice success

Language: Английский

Citations

0
The function and effectiveness of MSCs in preclinical models of diseases DOI
Z. Xie, Hu Zhou,

Tingting Ou

et al.

IntechOpen eBooks, Journal Year: 2024, Volume and Issue: unknown

Published: July 4, 2024

Mesenchymal stem cells (MSCs) have shown immense promise across diverse fields, particularly in treating various diseases. A multitude of preclinical investigations, encompassing both laboratory cellular-level studies and animal trials, demonstrated the significant effectiveness MSCs addressing a broad spectrum These collectively highlight enormous potential therapies utilizing range medical scenarios. From neurological cardiovascular disorders to autoimmune musculoskeletal disorders, including recent challenges like COVID-19, present therapeutic possibilities due their versatile capabilities. discoveries lay robust foundation for further clinical research eventual translation MSC-based treatments into mainstream practice, offering renewed optimism patients contending with complex conditions.

Language: Английский

Citations

0